Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.200
-0.010 (-0.83%)
Jun 20, 2025, 1:09 PM - Market open
Longeveron Revenue
Longeveron had revenue of $381.00K in the quarter ending March 31, 2025, a decrease of -30.47%. This brings the company's revenue in the last twelve months to $2.23M, up 127.51% year-over-year. In the year 2024, Longeveron had annual revenue of $2.39M with 237.38% growth.
Revenue (ttm)
$2.23M
Revenue Growth
+127.51%
P/S Ratio
6.81
Revenue / Employee
$89,000
Employees
25
Market Cap
18.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LGVN News
- 11 days ago - Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 4 weeks ago - Longeveron® to Attend BIO International Convention 2025 - GlobeNewsWire
- 5 weeks ago - Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewsWire
- 5 weeks ago - Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewsWire
- 3 months ago - Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Longeveron® to Present at the 37th Annual Roth Conference - GlobeNewsWire